Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner Purchases 158,000 Shares

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Richard Klausner purchased 158,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was purchased at an average cost of $0.60 per share, with a total value of $94,800.00. Following the purchase, the director now owns 843,365 shares in the company, valued at $506,019. This represents a 23.05 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lyell Immunopharma Trading Down 6.5 %

LYEL stock opened at $0.48 on Wednesday. Lyell Immunopharma, Inc. has a 1 year low of $0.48 and a 1 year high of $3.15. The company has a fifty day simple moving average of $0.62 and a 200 day simple moving average of $0.90. The firm has a market cap of $142.80 million, a PE ratio of -0.61 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The firm had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. As a group, analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a research note on Thursday, March 13th.

Institutional Trading of Lyell Immunopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Decheng Capital LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at approximately $7,622,000. Foresite Capital Management V LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at approximately $5,205,000. venBio Partners LLC acquired a new stake in Lyell Immunopharma in the 4th quarter valued at approximately $4,545,000. Geode Capital Management LLC grew its holdings in Lyell Immunopharma by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company’s stock valued at $2,648,000 after buying an additional 117,303 shares during the last quarter. Finally, State Street Corp grew its holdings in Lyell Immunopharma by 1.9% in the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock valued at $5,368,000 after buying an additional 71,233 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.